Showing results (31-40 of 60) with videos related to

Sort By:
Pageof 6
Eclinicalmedicine|July 6, 2023
Efficacy of early PET-CT directed switch to carboplatin and paclitaxel based definitive chemoradiotherapy in patients with oesophageal cancer who have a poor early response to induction cisplatin and capecitabine in the UK: a multi-centre randomised controlled phase II trialSomnath Mukherjee, Christopher N Hurt, Richard Adams, et al.
Lancet (London, England)|June 8, 2024
[177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2-3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 studySimron Singh, Daniel Halperin, Sten Myrehaug, et al.
The Lancet. Oncology|April 19, 2013
Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trialTom Waddell, Ian Chau, David Cunningham, et al.
The Lancet. Oncology|June 7, 2011
Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trialRichard A Adams, Angela M Meade, Matthew T Seymour, et al.
European Journal of Cancer (Oxford, England : 1990)|June 22, 2021
Oxaliplatin/capecitabine or carboplatin/paclitaxel-based preoperative chemoradiation for resectable oesophageal adenocarcinoma (NeoSCOPE): Long-term results of a randomised controlled trialSomnath Mukherjee, Christopher Hurt, Ganesh Radhakrishna, et al.
Eclinicalmedicine|October 3, 2022
Use of a non-endoscopic immunocytological device (Cytosponge™) for post chemoradiotherapy surveillance in patients with oesophageal cancer in the UK (CYTOFLOC): A multicentre feasibility studyChristopher M Jones, Heather O'Connor, Maria O'Donovan, et al.
The Lancet. Oncology|June 22, 2014
Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trialSusan J Dutton, David R Ferry, Jane M Blazeby, et al.
The Lancet. Oncology|April 2, 2021
Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trialAngela Lamarca, Daniel H Palmer, Harpreet Singh Wasan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 13, 2021
Capecitabine Versus Active Monitoring in Stable or Responding Metastatic Colorectal Cancer After 16 Weeks of First-Line Therapy: Results of the Randomized FOCUS4-N TrialRichard A Adams, David J Fisher, Janet Graham, et al.
The Lancet. Oncology|March 6, 2017
Vandetanib plus gemcitabine versus placebo plus gemcitabine in locally advanced or metastatic pancreatic carcinoma (ViP): a prospective, randomised, double-blind, multicentre phase 2 trialGary Middleton, Daniel H Palmer, William Greenhalf, et al.
Pageof 6